Psychiatric Quarterly

, Volume 83, Issue 2, pp 177–185 | Cite as

Bupropion Versus Sertraline in the Treatment of Depressive Patients with Binge Eating Disorder: Retrospective Cohort Study

  • Carmela Calandra
  • Rina Giuseppa Russo
  • Maria Luca
Original Paper


This study sought to compare Bupropion versus Sertraline in the treatment of depressed patients with Binge Eating Disorder (BED) prescribed off-label. Medical records of outpatients with diagnosis of BED and Depression (DSM-IV-TR criteria) were selected: 15 patients were treated with bupropion 150 mg/per day, and 15 with sertraline 200 mg/per day. During the screening and control visits (2°–6°–14°–24° week), the selected patients were first weighed and then evaluated using the following questionnaires: Binge Eating Disorder-Clinical Interview (BEDCI), Beck Depression Inventory (BDI), State-Trait Anxiety Inventory X (STAI-X) and Arizona Sexual Experience Scale (ASEX). Both drugs reduced anxious-depressive symptoms and binge frequency: Bupropion showed a better effectiveness in reducing weight and improving sexual performances; weight loss related to it was proportional to the body mass index. Bupropion may be associated with more weight loss in BED, depressed patients than sertraline.


Binge Eating Disorder Depression Body Mass Index Sexual performances 



The authors would like to thank Dr. Antonina Luca from Catania for her precious help in the first review of this article.


  1. 1.
    American Psychiatric Association: Practice guideline for the treatment of patients with eating disorders, third edition. American Journal of Psychiatry 163:4–54, 2006Google Scholar
  2. 2.
    Støving RK, Andries A, Brixen K, et al.: Gender differences in outcome of eating disorders: A retrospective cohort study. Psychiatry Research 186(2–3):362–366, 2010PubMedGoogle Scholar
  3. 3.
    Feldman MB, Meyer IH: Comorbidity and age of onset of eating disorders in gay men, lesbians, and bisexuals. Psychiatry Research 180:126–131, 2002CrossRefGoogle Scholar
  4. 4.
    Striengel-Moore RH, Cachelin FM, Dohm FA, et al.: Comparison of binge eating disorder and bulimia nervosa in a community sample. International Journal of Eating Disorders 29:157–165, 2001CrossRefGoogle Scholar
  5. 5.
    Pope HG Jr, Lalonde JK, Pindyck LJ, et al.: Binge eating disorder: A stable syndrome. American Journal of Psychiatry 163:2181–2183, 2006PubMedCrossRefGoogle Scholar
  6. 6.
    Brownley KA, Berkman ND, Sedway JA, et al.: Binge Eating Disorder treatment: A systematic review of randomized controlled trials. International Journal of Eating Disorders 40:337–348, 2007PubMedCrossRefGoogle Scholar
  7. 7.
    Carter WP, Hudson JI, Lalonde JK, et al.: Pharmacologic treatment of Binge Eating Disorder. International Journal of Eating Disorders 34:74–88, 2003CrossRefGoogle Scholar
  8. 8.
    Hudson JI, Carter WP, Pope HG Jr: Antidepressant treatment of binge eating disorder: Research findings and clinical guidelines. Journal of Clinical Psychiatry 57:73–79, 1996PubMedGoogle Scholar
  9. 9.
    Arnold LM, McElroy SL, Hudson JI, et al.: A placebo-controlled, randomized trial of fluoxetine in the treatment of binge-eating disorder. Journal of Clinical Psychiatry 63:1028–1033, 2002PubMedCrossRefGoogle Scholar
  10. 10.
    Pearlstein T, Spurell E, Hohlstein LA, et al.: A double-blind, placebo-controlled trial of fluvoxamine in binge eating disorder: A high placebo response. Archives of Women’s Mental Health 6:147–151, 2003PubMedCrossRefGoogle Scholar
  11. 11.
    Ricca V, Manucci E, Mezzani B, et al.: Fluoxetine and fluvoxamine combined with individual cognitive-behaviour therapy in binge eating disorder: A one year follow up study. Psychotherapy and Psychosomatics 70:298–306, 2001PubMedCrossRefGoogle Scholar
  12. 12.
    Hirschfeld RM: Long-term side effects of SSRIs: Sexual dysfunction and weight gain. Journal of Clinical Psychiatry 64:20–24, 2003PubMedCrossRefGoogle Scholar
  13. 13.
    McElroy SL, Casuto LS, Nelson EB, et al.: Placebo-controlled trial of sertraline in the treatment of binge eating disorder. American Journal of Psychiatry 157:1004–1006, 2000PubMedCrossRefGoogle Scholar
  14. 14.
    Leonbruni P, Pierò A, Brustolin A, et al.: A 12 to 24 weeks pilot study of sertraline treatment in obese women binge eaters. Human Psychopharmacology 21:181–188, 2006CrossRefGoogle Scholar
  15. 15.
    McElroy SL, Hudson JI, Malhorta S, et al.: Citalopram in the treatment of binge eating disorder: A placebo controlled trial. Journal of Clinical Psychiatry 64:807–813, 2003PubMedCrossRefGoogle Scholar
  16. 16.
    Guerdjikova AI, McElroy SL, Kotwal R, et al.: High dose escitalopram in the treatment of binge eating disorder with obesity: A placebo controlled monotherapy trial. Human Psychopharmacology 23:1–11, 2008PubMedCrossRefGoogle Scholar
  17. 17.
    Gadde KM, Parker CB, Maner LG, et al.: Bupropion for weight loss: An investigation of efficacy and tolerability in overweight and obese women. Obesity Research 9:544–551,2001PubMedCrossRefGoogle Scholar
  18. 18.
    Jain AK, Kaplan RA, Gadde KM, et al.: Bupropion SR vs placebo for weight loss in obese patients with depressive symptoms. Obesity Research 10:1049–1056, 2002PubMedCrossRefGoogle Scholar
  19. 19.
    Anderson JW, Greenway FL, Fujioka K, et al.: Bupropion SR enhances weight loss: A 48-week double-blind, placebo-controlled trial. Obesity Research 10:633–641, 2002PubMedCrossRefGoogle Scholar
  20. 20.
    Jefferson JW, Rush AJ, Nelson JC, et al.: Extended-release bupropion for patients with major depressive disorder presenting with symptoms of reduced energy, pleasure, and interest: Finding from a, randomized, double-blind placebo-controlled study. Journal of Clinical Psychiatry 67:865–873, 2006PubMedCrossRefGoogle Scholar
  21. 21.
    Jamerson BD, Krishnana KR, Roberts J, et al.: Effect of bupropion SR on specific symptom clusters of depression: Analysis on the 31-item Hamilton Rating Scale for Depression. Psychopharmacology Bulletin 37:67–78, 2003PubMedGoogle Scholar
  22. 22.
    American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders Text Revision (DSM-IV-TR), 4th edn. Washington, DC, American Psychiatric Association, 2002Google Scholar
  23. 23.
    Beck AT, Steer RA: Beck Depression Inventory, Manual. San Antonio, TX, The Psychological Corporation, 1993Google Scholar
  24. 24.
    Bocali C: Beck Depression Inventory. PsicoLab-Laboratorio di ricerca e sviluppo in Psicologia, 2006 (Italian)Google Scholar
  25. 25.
    First MB, Spitzer RI, Gibbon M, et al.: Structured Clinical Interview for DSM-IV Axis I Disorders-Outpatient Edition (SCID-O/P, version 2.0). New York, Biometric Research, New York State Psychiatric Institute, 1996Google Scholar
  26. 26.
    First MB, Gibbon M, Spitzer RI, et al.: Structured Clinical Interview for DSM-IV Axis II Personality Disorders (SCID-II). Washington, DC, American Psychiatric Press, 1997Google Scholar
  27. 27.
    Report of the World Health Organization Consultation of Obesity, Preventing and Managing the Global Epidemic of Obesity. Geneva, WHO, 1996Google Scholar
  28. 28.
    Spitzer RL, Yanovsky SZ, Marcus MD: Binge Eating Clinical Interview. Pittsburgh, HaPI Record, 1994Google Scholar
  29. 29.
    Richter P, Werner J, Heerlein A, et al.: On the validity of the Beck Depression Inventory. A review. Psychopathology 31:160–168, 1998PubMedCrossRefGoogle Scholar
  30. 30.
    Spielberger CD: Manual for the State-Trait Anxiety Inventory, Revised Edition. Palo Alto, CA, Consulting Psychologists Press, 1983Google Scholar
  31. 31.
    Oei TP, Evans L, Crook GM: Utility and validity of the STAI with anxiety disorder patients. The British Journal of Clinical Psychology 29(Pt 4):429–432, 1990PubMedCrossRefGoogle Scholar
  32. 32.
    McGahuey CA, Gelenberg AJ, Laukes CA, et al.: The Arizona Sexual Experience Scale (ASEX): Reliability and validity. Journal of Sex and Marital Therapy 26:25–40, 2000PubMedCrossRefGoogle Scholar
  33. 33.
    Calandra C, Terranova F, Loiacono P, et al.: Bupropione nel trattamento del disturbo depressivo maggiore: confronto con paroxetina. Italian Journal of Psychopathology 16:128–133, 2010 (Italian)Google Scholar
  34. 34.
    Croft H, Houser TL, Jamerson BD, et al.: Effect on body weight of bupropion SR in patients with major depression treated for 52 weeks. Clinical Therapeutics 24:662–672, 2002PubMedCrossRefGoogle Scholar
  35. 35.
    Fava M, Rush AJ, Thase ME, et al.: 15 years of clinical experience with bupropion HCl: From bupropion to bupropion-SR to bupropion-XL. The Primary Care Companion to the Journal of Clinical Psychiatry 7:106–113, 2005CrossRefGoogle Scholar
  36. 36.
    Thase ME, Haight BR, Richard N, et al.: Remission rates following antidepressant therapy with bupropion or selective serotonin reuptake inhibitors: A meta-analysis of original data from 7 randomized controlled trials. Journal of Clinical Psychiatry 66:974–981, 2005PubMedCrossRefGoogle Scholar
  37. 37.
    Billes SK, Cowley MA: Catecholamine reuptake inhibition causes weight loss by increasing locomotor activity and thermogenesis. Neuropsychopharmacology 33:1287–1297, 2008PubMedCrossRefGoogle Scholar
  38. 38.
    Monteleone P, Santonastaso P, Mauri M, et al.: Investigation of the serotonin transporter regulatory region polymorphism in bulimia nervosa: Relationships to harm avoidance, nutritional parameters, and psychiatric comorbidity. Psychosomatic Medicine 68:99–103, 2006PubMedCrossRefGoogle Scholar
  39. 39.
    Lloyd-Richardson EE, King TK, Forsyth LH, et al.: Body image evaluations in obese females with binge eating disorder. Eating Behaviors 1:161–171, 2000PubMedCrossRefGoogle Scholar
  40. 40.
    Steiger H, Joober R, Israel M, et al.: The 5HTTLPR polymorphism, psychopathologic symptoms, and platelet [3H-] paroxetine binding in bulimic syndromes. International Journal of Eating Disorders 2005;37:57–60, 2005PubMedCrossRefGoogle Scholar
  41. 41.
    Vinai P, Todisco P: Eziopatogenesi. La fame infinita. Turin, Centro Scientifico Editore, pp. 33–44, 2008 (Italian)Google Scholar
  42. 42.
    Safarinejad MR: The effects of the adjunctive bupropion on male sexual dysfunction induced by a selective serotonin reuptake inhibitor: A double-blind placebo-controlled and randomized study. BJU International 106:840–847, 2010PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  • Carmela Calandra
    • 1
  • Rina Giuseppa Russo
    • 1
  • Maria Luca
    • 1
  1. 1.Department of Medical and Surgery Specialties, Psychiatry Unit of the University Hospital “Policlinico-Vittorio Emanuele” of CataniaUniversity of CataniaCatania (Sicily)Italy

Personalised recommendations